November 2, 2023Open Access

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with IgA nephropathy, 12 months of treatment with sibeprenlimab resulted in a significantly greater decrease in proteinuria than placebo. (Funded by Visterra; ENVISION ClinicalTrials.gov number, NCT04287985; EudraCT number, 2019-002531-29.).

Bookmark

View Full Paper

Cite This Study

Mathur et al. (Thu,) studied this question.

synapsesocial.com/papers/69d978d05e5bcb4e3b836b18 https://doi.org/https://doi.org/10.1056/nejmoa2305635

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers2022 · 44 citations
2A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy2019 · 90 citations
3Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies1999 · 486 citations
4The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification2009 · 1,236 citations
5BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells2004 · 1,120 citations

Bookmark

View Full Paper